Stay updated on Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.

Latest updates to the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedMajor change: page now includes a funding/status notice and a new v3.2.0 revision, replacing v3.0.2.SummaryDifference13%

- Check44 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; Back to Top element removed.SummaryDifference0.8%

- Check51 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.8%

- Check58 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location details, while removing specific state, country, and city information. This indicates a shift in how location information is presented.SummaryDifference8%

- Check73 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.3%

- Check80 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11, indicating a revision in the content.SummaryDifference0.3%

Stay in the know with updates to Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.